Hepatobiology and Toxicology COBRE

肝脏生物学和毒理学 COBRE

基本信息

批准号：
10026250
负责人：
CRAIG J. MCCLAIN
金额：
$ 234万
依托单位：
UNIVERSITY OF LOUISVILLE
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-10 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10026250
关键词：
Acute Liver Failure Address Adult Affect Alcoholic Liver Diseases American Area Basic Science Biomedical Research Centers of Research Excellence Child Cirrhosis Collaborations Communication Communities Complex Core Facility Data Analyses Development Diabetes Mellitus Discipline Drug Interactions Drug abuse Ensure Environment Enzymes FDA approved Fostering Funding Goals Grant Health Hepatitis A Hepatitis B Hepatitis C Home Homelessness Industrialization Industry Injury International Kentucky Laboratories Link Liver Liver Failure Liver diseases Mentors Metabolic syndrome Metabolism Molecular Target Morbidity - disease rate National Institute on Alcohol Abuse and Alcoholism Obesity Organ Overweight Pharmaceutical Preparations Pharmacotherapy Phase Phase I Clinical Trials Prevention Primary carcinoma of the liver cells Process Program Sustainability Publications Research Research Infrastructure Research Personnel Research Project Grants Resources Scientist Structure Technology Therapeutic Toxic Environmental Substances Toxicant exposure Toxicology Translational Research United States National Institutes of Health Universities University resources biobank career development clinical practice education research experience liver injury liver transplantation member multidisciplinary non-alcoholic fatty liver disease nonalcoholic steatohepatitis novel novel therapeutics nutrition personalized medicine prevent programs recruit success toxicant viral liver disease

项目摘要

The University of Louisville (UofL) Hepatobiology and Toxicology (H&T) COBRE is a unique thematic center focused on liver research. The UofL H&T COBRE concentrates on the mechanisms and therapeutic strategies for multiple forms of liver disease/injury, including: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis—the most common liver disease in the US/worldwide, and is highly linked to the metabolic syndrome; Alcoholic Liver Disease—a common problem among those who drink; Environmental Toxicant Induced Liver Injury—an increasingly recognized problem, and Louisville has been a leader in this area; Hepatitis B and C—important causes of cirrhosis and hepatocellular carcinoma worldwide; Personalized Medicine—an increasingly important factor in medication efficacy, and most drugs are metabolized in the liver; and Drug-Induced Liver Injury—the most common reason drugs are removed from the market and an important cause of liver failure. This COBRE brings together experienced senior mentors/investigators and promising junior investigators to perform cross-cutting research on the unique topics of Hepatobiology and Toxicology. We address critical barriers in our understanding of the development/ progression of liver disease and we define targets for prevention/treatment that could transform clinical practice. Specific Aims of the Hepatobiology and Toxicology COBRE are to: 1. Expand and strengthen a thematically-focused program in Hepatobiology and Toxicology that helps build and sustain the overall research infrastructure at UofL. 2. Expand and strengthen the multidisciplinary program in research education, mentoring and career development in Hepatobiology and Toxicology, and systematically track and evaluate the progress. 3. Provide the necessary research resources and translational science/basic technologies to support state-of- the-art research in Hepatobiology and Toxicology and to ensure sustainability of the program. 4. Discover new mechanisms/molecular targets and effective means for preventing and/or treating liver diseases/toxicant exposures and communicate our findings to the public. In summary, Phase I strengthened UofL’s biomedical research infrastructure through the establishment of a thematic multidisciplinary center in hepatobiology and toxicology to enhance the ability of investigators to compete for independent funding. In Phase I, we met or exceeded our metrics, including 1) four of our investigators transitioning to independent research funding; 2) 91 mentee and 162 total publications; 3) new renovated laboratory space; 4) numerous presentations; 5) establishing new collaborations; and 6) >$75 million in total new grant funding by H&T members. This Phase II proposal builds on our Phase I success, extends and strengthens the scope of the program, and provides a roadmap for sustainability.

路易斯维尔大学 (UofL) 肝生物学和毒理学 (H&T) COBRE 是一个独特的主题 UofL H&T COBRE 中心专注于肝脏研究，专注于机制和治疗。针对多种形式的肝病/损伤的策略，包括：非酒精性脂肪肝病/非酒精性肝病脂肪性肝炎——美国/全世界最常见的肝脏疾病，与代谢性肝炎高度相关酒精性肝病——饮酒者的常见问题；诱发性肝损伤——一个日益被认识到的问题，路易斯维尔一直是该领域的领导者；乙型和丙型肝炎——全球肝硬化和肝细胞癌的重要病因；医学——药物疗效日益重要的因素，大多数药物在肝脏中代谢；和药物引起的肝损伤——药物被撤出市场的最常见原因，也是药物引起的肝损伤的原因。该 COBRE 汇集了经验丰富的高级导师/研究人员和有前途的初级研究人员对肝生物学和肝生物学的独特主题进行跨领域研究我们解决了理解肝病发生/进展的关键障碍。我们定义了可以改变临床实践的预防/治疗目标。肝生物学和毒理学 COBRE 的具体目标是： 1. 扩大和加强肝生物学和毒理学方面的主题计划，以帮助建立并维持伦敦大学的整体研究基础设施。 2. 扩大和加强研究教育、指导和职业方面的多学科计划肝生物学和毒理学的发展，并系统地跟踪和评估进展。 3. 提供必要的研究资源和转化科学/基础技术以支持现状肝生物学和毒理学方面的最先进研究，并确保该计划的可持续性。 4. 发现预防和/或治疗肝脏的新机制/分子靶点和有效手段疾病/有毒物质暴露并向公众传达我们的发现。总之，第一阶段通过建立以下机构加强了伦敦大学的生物医学研究基础设施：肝生物学和毒理学专题多学科中心，旨在提高研究人员的能力在争取独立资金的过程中，我们达到或超过了我们的指标，包括 1) 四个指标。研究人员转向独立研究资助；2) 91 名受训者和总共 162 篇出版物；3) 翻新的实验室空间；4) 大量的演示；以及 6) > 75 美元 H&T 成员提供的新赠款总额为 100 万美元。第二阶段提案建立在我们第一阶段成功的基础上，扩大和加强了该计划的范围，并提供了可持续发展的路线图。